Friday, 16 October 2026European Markets

OL GROUPE Stock Went Down By Over 9% So Far On Monday

Loading stream...

entertainment and media company ol groupe (cac 40: olg.pa) appears to be experiencing difficulties in financial markets as its shares fell by 9.47% on monday morning at 11:05 est, dipping to eur1.87. this comes on the heels of a previous price increase but represents a significant drop as compared to the cac 40 index's negligible decrease of 0.23% after a prior session's increase.

ol groupe performance: a glance at the figures

ol groupe is best known for its management of the olympique lyonnais football club and the operations of groupama stadium. by the close of the last trading session, the company's shares stood at eur2.06, indicating a sharp 31.1% decline from the 52-week high of eur2.99. this sits significantly below its annual low value of eur2.10. as of now, the trailing twelve-month earnings per share (eps) for ol groupe is eur-1.4, further compounded by a drastic negative return on equity (roe) figure of -89.25%. this figure gives us an idea of the company's efficiency in generating returns relative to the equity shareholders have invested.

ol groupe revenue and share trading highlights

on a brighter note, ol groupe reported an impressive year-on-year quarterly revenue increase of 21.4%, amounting to eur176.55 million over twelve months. this uptick, however, appears to have been overshadowed by negative market sentiment, resulting in poor eps and roe numbers. looking at ol groupe shares, it becomes immediately apparent that their trading volume is low. on the first trading day of the week, the reported trading volume reached just 9,813, far below the daily average of 291,452. such scant trading volumes hint at a lack of interest among buyers and sellers, leading to thin trading which may increase volatility for the company's share prices.

more news about ol groupe (olg.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com